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ATMIntegration of human papillomaviruses into that of the host promotes genomic instability and progression to
cancer; factors that promote integration remain to be fully identiﬁed. DNA damage agents can promote
double strand breaks during DNA replication providing substrates for integration and we investigated the
ability of DNA damage to regulate HPV E1 and E2 mediated DNA replication. Results demonstrate that HPV
E1 and E2 replication is not arrested following DNA damage, both in vivo and in vitro, while replication by
SV40 Large T antigen is arrested and ATR is the candidate kinase for mediating the arrest. LTAg is a target for
PIKK DNA damage signalling kinases, while E1 is not. We propose that the failure of E1 to be targeted by
PIKKs allows HPV replication in the presence of DNA damaging agents. Such replication will result in double
strand breaks in the viral genome ultimately promoting viral integration and cervical cancer.y), i.morgan@vet.gla.ac.uk
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Human papillomaviruses (HPV) are double stranded DNA viruses
that are causative agents in a number of human diseases including
cervical cancer (zur Hausen, 2009). Throughout the viral life cycle two
viral proteins, the replicative helicase E1 and the DNA binding protein
E2, are required for viral genome replication (Wilson et al., 2002). E2
is a DNA binding protein that binds to target sequences around the
viral origin and recruits the E1 helicase which forms a di-hexameric
complex that replicates the viral genome via interaction with host
proteins (Steger et al., 1996). In addition to its role in the initiation of
viral DNA replication, the E2 protein regulates transcription of the E6
and E7 encoding sequences via an adjacent promoter. In most
circumstances E2 represses this promoter and therefore controls the
levels of E6 and E7 protein present in the cell (Thierry, 2009).
High risk human papillomaviruses (HPV) are causative agents in
cervical cancer and are increasingly implicated in the development ofhead and neck cancer (Psyrri et al., 2009). One of the hallmarks of
cervical cancer is viral genome integration into that of the host
resulting in disruption of the HPV E2 open reading frame (Pett and
Coleman, 2007). This integration allows for increased expression of E6
and E7 promoting cell growth, genomic instability and carcinogenesis.
In addition to the increased expression of the transforming proteins
viral integration may also promote genome damage via partial
replication of the integrated genomes by E1 and E2 proteins (Kadaja
et al., 2007; Kadaja et al., 2009a; Kadaja et al., 2009b). This partial
replication results in dsDNA breaks (DSBs) generating substrates for
non-homologous end joining that could be mutagenic and therefore
contribute to carcinogenesis.
It is clear that viral integration contributes towards the transformed
phenotype from studies carried out in cervical tumour samples and also
using in vitromodel systems (Wentzensen et al., 2004; Dall et al., 2008).
Most tumours have integrated HPV genomes, while some have a
mixture of episomal and integrated viral genomes (Vinokurova et al.,
2008). The factors that promote viral integration have been less well
studied. For integration to occur there must be a double strand break in
the circular viral genome and this broken genome can then act as a
substrate for viral integration into thehost genomevianon-homologous
end joining. One way for this breakage to occur is for viral replication to
occur in the presence of DNA damaging agents, promoting double
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response pathwaysmediated by theATR/ATMpathways followingDNA
damage. These pathways arrest ongoing DNA replication, prevent new
initiation, maintain stalled DNA replication forks, and activate DNA
damage repair pathways (Jackson and Bartek, 2009). Following DNA
repair, DNA replication can restart from the stalledDNA replication forks
and new origins are ﬁred to complete genome replication. In this way,
the cell can ensure that damaged genomes are not replicated therefore
maintaining genomic integrity. The precise targets of the DNA damage
pathways that allow the immediate stalling of DNA replication forks are
not completely clear, although several of the MCM proteins in the
replicative helicase complex are phosphorylated by ATR/ATM. It is
proposed that this phosphorylation of the helicase contributes to the
stalling and maintenance of DNA replication forks in the presence of
DNA damaging agents (Cortez et al., 2004; Ishimi et al., 2003a, b).
This report demonstrates that etoposide, a Topoisomerase IIa
inhibitor that generates DSBs resulting in DNA damage signalling that
arrests DNA replication and the cell cycle (Minocha and Long, 1984),
does not result in inhibition of E1–E2 DNA replication. E1–E2 DNA
replication is not inhibited by the presence of etoposide even though
the ATR pathway is activated. As a control we investigated the
regulation of SV40 Large T antigen (LT) mediated DNA replication,
which uses a very similar DNA replication strategy and uses the same
cellular replication factors as SV40 (Muller et al., 1994, Melendy et al.,
1995). Unlike PV E1 DNA replication, LT DNA replication is arrested
following etoposide treatment. We conﬁrm these results in vitro: LT
DNA replication is arrested by addition of DSBs, while HPV DNA
replication is not. Further, we show this arrest to be sensitive to the
DNA damage PIKK inhibitor, wortmannin, and in vivo and in vitro
studies with kinase speciﬁc inhibitors suggest that ATR is responsible
for replication arrest. We demonstrate that LT is phosphorylated by
the ATR/ATM kinases while E1 is not. We propose a model in which
the failure of E1 to be phosphorylated by ATR/ATM allows E1–E2
mediated DNA replication in the presence of DNA damage therefore
promoting viral genome double strand breaks.
Results
E1–E2 mediated DNA replication is not arrested by etoposide
To investigate whether E1–E2 mediated DNA replication is
arrested by DNA damage, we carried out transient DNA replication
assays in 293T cells using the real-time PCR protocol developed in our
lab (Taylor and Morgan, 2003; Morgan and Taylor, 2005). We used
etoposide as the DNA damaging agent. Etoposide inhibits Topoisome-
rase IIa, resulting in double strand DNA breaks (DSBs) during the S
phase of the cell cycle. As a control for inhibition of DNA replication,
we also used the replicative DNA polymerase (alpha/delta/epsilon)
inhibitor aphidicolin (Ikegami et al, 1978). This drug arrests both
cellular and viral (HPV and SV40) DNA replication. For comparison,
we investigated the ability of these reagents to interfere with SV40
Large T antigen (LT)-dependent DNA replication. Fig. 1a details the
results obtained with HPV11 E1 and E2; identical results were
obtained with HPV16 E1 and E2 proteins (data not shown). No
DNA replication signal is detected in the non-transfected cells, nor
when a plasmid containing the HPV origin (pOriM) is transfectedwith
or without an E1 expression plasmid alone are co-transfected (lanes
1–3). As expected, DNA replication is only detected when an E2
expression plasmid is also co-transfected (lane 4). When the cells are
treated with aphidicolin following transfection there is a minimal
level of DNA replication that presumably occurs prior to application of
the drug (lane 6). When etoposide is added to the cells, there is no
reduction in DNA replication and if anything there is a small increase
in E1–E2 mediated DNA replication (lane 5). As this was a surprising
result, we wanted to conﬁrm that this was not due to 293T cells
not receiving or responding to a DNA replication arrest signal. Toinvestigate this LT-mediated DNA replication was also evaluated
(Fig. 1b). 293T cells express SV40 LT constitutively. Without any
plasmid transfected there is no signal (lane 1) and when a plasmid
containing the luciferase gene but lacking the SV40 origin is added
there remains no detectable signal (lane 2, p−SV40 ori). But when a
plasmid containing the SV40 origin is added and replication is
evaluated using a luciferase probe and primer set there is clear
replication detected (lane 3, p+SV40 ori). As with E1–E2 mediated
DNA replication, aphidicolin substantially reduces the DNA replication
signal as expected (lane 5). When etoposide is added the LT-
dependent DNA replication is also substantially reduced, in striking
contrast to the results obtained with E1–E2 dependent replication.
These results were reproducible with camptothecin (not shown),
another DNA damaging agent that induces DNA double strand breaks
during S phase.
In vitro results show that LT replication arrest is inhibited via a checkpoint
response, while E1–E2 replication is not
To demonstrate that this difference in DNA replication sensitivity
to etoposide treatment is due to an authentic DNA damage checkpoint
response, dependence on checkpoint kinases needs to be demon-
strated. However, etoposide is highly toxic to cells deﬁcient in
checkpoint kinase function or in the presence of checkpoint kinase
inhibitors, therefore experiments such as those in Fig. 1 were not
feasible (data not shown). Hence, in vitro viral DNA replication assays
were utilized to address this question. In vitro DNA replication assays
were carried out using established protocols for both LT and E1
mediated replication. To adapt this protocol to address checkpoint
arrest, plasmid DNA digested with a restriction enzyme (to generate
DSBs) was added to the cell extract to determine whether DSBs
produce a DNA damage signal that can regulate LT or E1 mediated in
vitro DNA replication. Circular undigested plasmid DNA provided a
control demonstrating that addition of the same amount of DNA
without DSB ends would not alter the DNA replication activity of LT or
E1. Fig. 2a shows that addition of undigested supercoiled DNA had no
affect on LT replication (compare lanes 1 and 2) while addition of
linearised DNA resulted in a signiﬁcant reduction in LT replication
(compare lanes 1 and 4). To determine whether this arrest in LT
replication was due to a checkpoint response, wortmannin (an
inhibitor of the DSB-triggered PI3 kinase-related protein kinases
(PIKKs), ATM, ATR and DNA-PK) was added (Wang et al., 2005).
Addition of wortmannin did not affect replication in the presence of
the supercoiled DNA (compare lanes 1 and 3) while it relieved the
inhibition of LT replication by the linearised DNA (compare lanes 4
and 5). These results demonstrate two things: ﬁrstly that DNA ends
can induce an arrest of LT-mediated DNA replication; and secondly,
that wortmannin can relieve this inhibition. To determine whether
the DSB-induced wortmannin-sensitive signal could interfere with E1
mediated DNA replication in vitro, identical experiments were carried
out with E1. E1 mediated DNA replication was not affected by
linearised DNA fragments (Fig. 4b), nor by treatment with
wortmannin (data not shown). Therefore, these in vitro results
mimic what is observed in vivo as shown in Fig. 1; LT replication is
sensitive to DNA damage signalling while E1 mediated replication is
not. Further, they show that this response is dependent on the PIKKs,
the kinases that initiate the cellular DNA damage checkpoint path-
ways. To investigate which of the PIKKs was responsible for the
inhibition of LT induced DNA replication these experiments were
carried out in the presence of speciﬁc DNA damage kinase inhibitors
that target DNA-PK and ATM; there is no speciﬁc inhibitor of ATR.
Fig. 2c is a summary of four individual experiments quantiﬁed as
described. Addition of either a DNA-PK-speciﬁc inhibitor (NU7026), a
ATM-speciﬁc inhibitor (KU55933), or both kinase inhibitors, pre-
vented replication arrest by addition of DNA fragments (such as
that seen with wortmannin). These results suggest that it is the
Fig. 1.HPVE1andE2mediatedDNA replication is not arrested byDNAdamage agents,while SV40LTAg replication is. a) 293T cellswere transfectedwith 100 pgof pOriM (lanes 2–6), 5 μg
of pCMV-E1 (lanes 3–6) and 2 μg of pCMV-E2 (lanes 4–6). The day after transfection, cells were left untreated (lanes 1–4) or treated with 50 mM of etoposide (lane 5) or 2.5 mg/ml of
aphidicolin (lane 6). Forty-eight hours later lowmolecularweightDNAwas harvested from the cells for replication assays. The results shown represent the summary of three experiments
and the results are standardised to E1+E2without treatment (lane 4) equalling 1. b) 293T cellswere transfectedwith 1 ngof luciferase gene containingplasmidDNA(lanes2–5). In lane2,
the plasmid contained no SV40 origin of replication, in lanes 3–5 the plasmid contained an SV40 origin of replication. The day after transfection, cells were left untreated (lanes 1–3) or
treated with 50 μM of etoposide (lane 4) or 2.5 mg/ml of aphidicolin (lane 5). Forty-eight hours later lowmolecular weight DNAwas harvested from the cells for replication assays. The
results shown represent the summary of three experiments and the results are standardised to LTAg without treatment (lane 3) equalling 1.
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DNA-PK was veriﬁed using the Promega DNA-PK assay kit; inhibition
of ATM was conﬁrmed by evaluation of the hyper-phosphorylation
of NBS1, conﬁrming that these inhibitors were functional in these
assays.)E1 is not a substrate for DNA damage signalling PIK kinases in vivo
In order to arrest DNA replication following DNA damage, an
enzymatic activity associated with DNA replicationmust be blocked. As
both of these viral replication complexes use the same cellular DNA
Fig. 2. HPV E1 and E2 mediated DNA replication is not arrested by DNA damage checkpoints in vitro while SV40 DNA replication is. a) In vitro SV40 DNA replication as described in
Materials and methods was carried out in the presence of 0.1% DMSO (lane 1). Undigested pUC19 DNA (50 ng) was added to HEK 293 cell extract prior to assembly of replication
reaction, either in the absence (lane 2) or presence of 20 μM wortmannin (lane 3). Restriction-enzyme digested pUC19 (50 ng) was added to the HEK 293 cell extract prior to the
assembly of SV40 replication reaction either in the absence (lane 4) or presence of 20 μMwortmannin (lane 5). b) Left panel— SV40 replication reactions were carried out as in panel
A lane 1 (except with no DMSO). Zero, 50 or 100 ng of restriction enzyme digested pUC19 DNAwas added as indicated. Right panel—HPV DNA replication reactions were carried out
as described in Materials and methods using the same extract and reaction buffer as in the left panel, varying only the replication template DNA and using HPV11 E1 in place of SV40
large T antigen. Either zero or 100 ng of restriction enzyme digested pUC19 DNA was added as indicated. c) Testing whether speciﬁc inhibitors can alleviate DNA replication
inhibition. The inhibitors indicated (DNA-PKi=NU7026; ATMi=KU55933) were added to the extracts on ice 5 min prior to addition of template and replication reaction
components (concentrations of the inhibitors given are ﬁnal concentration in the reaction). Replication levels were quantiﬁed as described in Materials and methods. Results shown
represent four independent experiments; error bars indicate the standard deviation.
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et al., 1987; Taylor et al, 2003) and PV DNA replication has been shown
to be dependent on the same cellular replication proteins as SV40 DNA
replication (Muller et al., 1994; Melendy et al., 1995), the most obvious
difference between the enzyme activities used by E1–E2 versus LT-
mediatedDNAreplication is theactual helicase itself. In addition, studies
have demonstrated that MCM proteins are targets for DNA damage
signalling pathways and it has been hypothesised that this phosphor-
ylation could contribute towards the arrest of DNA replication in the
presence of DNA damaging agents (Cortez et al., 2004; Ishimi et al.,
2003a, b). Studies have shown that DNA damage induced phosphory-
lation of LT by ATM at Ser120 and we postulated that etoposide
treatment resulted inphosphorylationof LT (Shi et al., 2005). Therehavebeen no corresponding studies carried out with E1 but we hypothesise
that E1 is not a substrate for the ATM/ATR signalling pathways allowing
replication in the presence of DNA damage. To investigate this 293T
cells, 293T cells expressing an HA-tagged E1, were treated with
etoposide and protein extracts immunoprecipitated with a phospho-
(Ser/Thr)-glutamine ATR/ATM substrate antibody (pS/Q antibody).
These immunoprecipitations were subjected to immunoblotting for E1
or LT. The pS/Q antibody is known to immunoprecipitate phosphory-
lated ATR/ATM substrates. In Fig. 3a the failure of the pS/Q antibody to
immunoprecipitate an HA-tagged HPV11 E1 is shown. The input E1
levels used in these experiments are shown in lanes 5–8 and the cells
were treated with 50 mM of etoposide for 30 min prior to cell harvest
and protein preparation. Treatment with etoposide does not result in
Fig. 3. LT Ag is a substrate for DNA damage kinases, while E1 is not. a) 293T cells were
transfected with 1 μg of HPV11 HA-E1 (lanes 3, 4 and 7, 8) or 1 μg of empty control
vector (lanes 1, 2 and 5, 6). Twenty-four hours later the cells were treated with 50 μMof
etoposide for 30 min (+) or left untreated (−) as indicated and protein extracts
prepared. A fraction of the protein extract was then immunoprecipitated with an S/Q
antibody (lanes 1–4) and the resultant precipitate probed with an HA antibody. It is
clear that no substantial amounts of HA-E1 are immunoprecipitated with the S/Q
antibody even though there are detectable levels of this protein in the input (lanes 7, 8).
b) 293T cells were transfected with 1 μg of HPV16 HA-E1 (lanes 3, 4 and 5, 6) or 1 μg of
empty control vector (lanes 1, 2). Twenty-four hours later the cells were treated with
50 μM of etoposide for 30 min (+) or left untreated (−) as indicated and protein
extracts prepared. A fraction of the protein extract was then immunoprecipitated with
an S/Q antibody (lanes 1–4) and the resultant precipitate probed with an HA antibody.
It is clear that no substantial amount of HA-E1 is immunoprecipitated with the S/Q
antibody even though there are detectable levels of this protein in the input (lanes 5, 6).
c) 293T cells were treated with 50 μM of etoposide for 0.5 h (+) or left untreated (−).
After treatment protein extracts were prepared and a fraction of this was then
immunoprecipitated with the S/Q antibody (lanes 1 and 2). The immunoprecipitates
were then immunoblotted for LTAg using pAb101. Lanes 3 and 4 show the input levels
of LTAg in the immunoprecipitation inputs.
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that there is very little E1 protein co-immunoprecipitatedwith thepS/Q
antibody, with no increase in precipitated E1 following etoposide
treatment (compare lanes 3 and 4). Fig. 3b details the results obtained
with HA-tagged HPV16 E1 where identical results are obtained,
suggesting that this protein is not a substrate for ATM/ATR. To evaluate
whether LT is an ATM/ATR substrate the same experiment was carried
out and the presence of the LT protein in the pS/Q immunoprecipitate
wasmonitored (Fig. 3c). In the input lanes (3 and 4) it is again clear that
following 30 min of etoposide treatment there is no degradation of LT.
However, in contrast to E1, following treatment with etoposide the pS/
Q antibody immunoprecipitates a signiﬁcant amount of LT demonstrat-
ing that following etoposide treatment, this protein is targeted by the
ATM/ATR kinases.
LT protein levels are reduced following extended exposure to etoposide
The DNA replication assay results in Fig. 1 are extended over 48 h
following etoposide treatment, not the 30 min used in Fig. 3. To
investigate the levels of the LT protein following extended etoposide
treatment an extended time course of etoposide treatment followedby LT western blotting was carried out and the results are shown in
Fig. 4a. The level of LT protein begins to drop after 8 h of exposure to
etoposide and after 24 h there is a signiﬁcant reduction in the level of
LT. To conﬁrm that etoposide induced a DNA damage response, a
phospho-Chk1 antibody was used and etoposide clearly induces Chk1
phosphorylation, a substrate for activated ATR (Zhao and Piwnica-
Worms, 2001). We also conﬁrmed that Chk2 was phosphorylated on
threonine 68 demonstrating that ATM is also activated (not shown).
This phosphorylation persists over the 24 hour period of the
experiment. Gamma-tubulin levels are shown as a loading control.
Fig. 4b shows that the level of the HPV16 E1 protein is not decreased
following 24 h of etoposide treatment, while phosphorylation of Chk1
demonstrates that a DNA damage signal was generated in the
presence of E1 and that it persisted throughout the 24 hour time
point. If anything the levels of E1 increase following 24 h of treatment
with etoposide. This demonstrates that E1 does not block activation of
ATR as around 90% of the cells express E1 following transfection (not
shown). The level of HPV16 E2 protein is also not decreased over a
24 hour time period following etoposide treatment (Fig. 4c), and
again, like E1, there is an increase in E2 protein levels suggesting a
stabilisation following DNA damage. The level of LT RNA in 293T cells
is reduced by two thirds following 24 h of etoposide treatment (not
shown). However, the level of LT protein is reduced to a greater
extent, suggesting that the decrease in LT levels may be due to more
than just the reduction in mRNA levels. In addition, the in vitro
experiments described in Fig. 2 demonstrate that the regulation of LT-
mediated DNA replication by DNA damaging agents is due to a direct
regulation of the LT protein. Therefore although there is a reduction in
LT RNA levels following etoposide treatment, this is unlikely to
completely explain the inhibition of DNA replication function. To
determine whether the reduction of LT is due to a proteasome-
mediated degradation, the proteasomal inhibitor MG132 was used in
the etoposide experiments. The result of this experiment is shown in
Fig. 4d where it is clear that blocking of proteasomal degradation by
treatment with MG132 blocks reduction of LT protein levels following
etoposide treatment.
Discussion
HPV are causative agents in cervical cancer and in the majority of
cases, the viral genome is integrated into that of the host. This
integration disrupts the E2 open reading frame resulting in relief of
transcriptional repression of the HPV oncogenes E6 and E7. Their
increased expression is proposed to promote genomic instability and
carcinogenesis (Pett and Coleman, 2007). In this report we have
investigated factors that could contribute towards viral genome
integration, speciﬁcally focusing on the role that DNA damage may
play in this process. The results show that E1–E2 mediated DNA
replication is not arrested in the presence of DNA damage, even
though an intact DNA damage response is mounted in the E1–E2
expressing cells. This failure to arrest results in replication in the
presence of DNA damaging agents increasing the risk of aberrant DNA
replication and promotion of DSBs generating substrates for viral
integration.
Previous studies on SV40 infection have demonstrated that the
DNA damage response is activated in the infected cells and that this
activation is required for a productive infection, phosphorylation of LT
on S120 results in a stimulation of replication (Shi et al, 2005). In
addition, SV40 infected cells alter the host DNA damage response by
targeting the MRN complex for degradation via the proteasome
(Digweed et al., 2002; Zhao et al., 2008). Therefore the host cell DNA
damage response is re-programmed by SV40 infection presumably to
promote viral DNA replication. More speciﬁcally it has also been
shown that expression of the LT protein by itself can promote genomic
instability by binding to Bub1 and interfering with the function of this
protein in mitosis (Cotsiki et al., 2004; Hein et al., 2009) as well as
Fig. 4. LTAg protein levels are reduced via the proteasome following etoposide treatment. a) 293T cells were treated with 50 μM of etoposide for the time periods shown and then
protein extracts prepared. These extracts were then western blotted for the proteins indicated. Chk1 S317 serves as a control to conﬁrm activation of the DNA damage response and
gamma-tubulin as a loading control. b) 293T cells were transfected with 1 μg of HPV16 HA-E1 plasmid and the following day cells left untreated (−) or treated with 50 μM of
etoposide (+) for the time periods shown. Protein extracts were then prepared and western blotted for the proteins indicated. Chk1 S317 serves as a control to conﬁrm activation of
the DNA damage response and gamma-tubulin as a loading control. c) 293T cells were transfected with 2 μg of HPV16 E2 plasmid and the following day cells left untreated (−) or
treated with 50 μMof etoposide (+) for the time periods shown. Protein extracts were then prepared andwestern blotted for the proteins indicated. Chk1 S317 serves as a control to
conﬁrm activation of the DNA damage response and gamma-tubulin as a loading control. d) 293T cells were treated with 50 mM etoposide (lanes 2 and 4) and/or MG132 (lanes 3
and 4) as indicated and protein extracts prepared 24 h later. Western blotting was then carried out for LTAg and gamma-tubulin as a loading control.
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pRb (Cheng et al., 2009). Paradoxically, DNA damage signals can
suppress SV40 DNA replication in mammalian cells via activation of
the DNA damage signalling kinases (Miao et al., 2003). 293T cells
retain the ability to signal via the DNA damage signalling kinases
despite stably expressing LT (Shirata et al., 2005). Clearly the results
describe here agree with these previous studies demonstrating arrest
of LT-mediated DNA replication following DNA damage. The reason
for the different responses of SV40 LT-mediated DNA replication
following either viral infection (activation of damage signalling
pathways and stimulation of replication) or treatment with DNA
damaging agents (which activate damage signalling pathways but
suppress replication) may be related to differential modiﬁcation of LT
in different circumstances. Phosphorylation of S120 results in
stimulation of LT replication function following viral infection and it
is possible that following exposure to DNA damaging agents LT is
differentially modiﬁed resulting in replication repression. Proteomic
and mutational studies will be required to determine whether this is
the case.
Signiﬁcantly, this report demonstrates that neither HPV11 nor
HPV16 E1 is a substrate for DNA damage kinases. Like SV40, recent
work has demonstrated that HPV can activate DNA damage signalling
kinases during their life cycle (Moody and Laimins, 2009) but unlike
SV40, DNA damage per se does not arrest E1/E2 mediated DNA
replication (this report). Therefore the difference in the DNA
replication response of LT and E1–E2 is likely related to either the
differential phosphorylation of LT and E1 following DNA damage, or to
differential interactions of these two viral proteins with cellular
factors phosphorylated by DNA damage response pathways. This is of
interest when considering cellular DNA replication and the responseto DNA damage. Previous work has demonstrated that following DNA
damage SV40 DNA replication control mimics that of cellular DNA
replication (Miao et al. 2003). Therefore the results presented here
strongly support the hypothesis that the replicative helicase is a direct
target for DNA damaging signalling kinases and that phosphorylation
by these kinases plays a key role in arresting DNA replication. Previous
studies have demonstrated phosphorylation of MCM proteins follow-
ing DNA damage (Cortez et al., 2004; Ishimi et al., 2003a, b) and it
seems clear that phosphorylation of these proteins is integral to the
arrest of DNA replication following DNA damage.
The apparent stabilisation of E1 and E2 following etoposide
treatment (Fig. 4) may be due to the arrest of the cells in S phase
where it has recently been shown that E2 is stabilised (Johansson et
al., 2009) and the ongoing replication by E1 and E2 due to non-
targeting of E1 by DNA damage response kinases. This would provide
an ideal environment to promote double stranded DNA breaks in the
replicating HPV genome promoting viral integration and progression
to cancer. Further investigations are merited to determine whether
agents such as estrogen, which can regulate the DNA damage
response (Pedram et al, 2009), promote double strand breaks in
HPV genomes therefore contributing to progression to cancer.
Materials and methods
Plasmids
pCMVHPV16 E2 plasmid (HPV16 E2) expresses a wild type HPV16
E2 protein from a CMV promoter. pCMV HPV16 E1 (HPV16 E2)
expresses a wild type HPV16 E1 protein from a CMV promoter.
pHPV16 E1HA (expresses the wild type HPV16 E1 protein) and
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tag, and were a kind gift from Mart Ustav. pOri16M (pOriM) contains
the HPV16 origin of replication cloned into pSKII (−) (Taylor and
Morgan, 2003). pGL3-control vector (p+SV40 ori) contains a SV40
promoter and luciferase gene. pGL3-basic vector (p−SV40 ori)
contains a luciferase gene but no SV40 promoter. pcDNA 3.1
(Invitrogen) was used as a carrier plasmid. The HPV11 E2 and E1
expression vectors were a kind gift from Dr Jacques Archambault,
University of Montreal. The DNA-PK and ATM inhibitors, NU7026 and
KU55933, were gifts from Dr. Graeme Smith, KuDOS Pharmaceuticals,
Division of Astra Zeneca. The HA-tagged E1 expression vectors were a
kind gift from Dr Mart Ustav, Estonian Biocentre, Tartu.
Cell growth and transfection
HEK-293T cells were cultured in DMEM (Dulbecco's modiﬁed
Eagles medium) supplemented with 10% (v/v) foetal calf serum and
1% (v/v) penicillin/streptomycin mixture (Invitrogen) at 37 °C in a 5%
CO2/95% air atmosphere.
Cells were plated out on 100 mm2 plates so as to achieve around
80% conﬂuence upon harvest. Cells were transiently transfected using
a standard calcium phosphate precipitation technique.
DNA replication assay
TransientDNA replication assayswere carried out in a similarmethod
as described previously (Taylor & Morgan, 2003). Brieﬂy 3×105 293T
cells were plated out andwere CaPO4 transfected the following daywith
the HPV replicative plasmids (pOriM, pCMV-E1 and pCMV-E2) or the
SV40 replicative plasmids (p−SV40 ori and p+SV40 ori). The following
morning cells were washed twice in PBS and left untreated, treated with
etoposide (Sigma) or aphidicolin (Sigma) then harvested 48 h later in
Hirt solution (10 mMEDTA, 0.5%SDS).DNAwasextractedandpuriﬁedas
described. DammethylatedDNAwasdigestedusingDpn1 (NewEngland
Biolabs) and ExoIII (New England Biolabs) to allow freshly replicated
pOriM/p+SV40 DNA to be measured. For real-time PCR assays, probe
and primers were designed to amplify the HPV and LT origin plasmids,
pOriM and p+/−SV40 respectively. pOriM: forward primer 5′
ATCGGTTGAACCGAAACCG 3′ , reverse primer 5′ TAACTT-
CTGGGTCGCTCCTG 3′ and probe 5′ 6-FAM-ACCAAAAGAGAACTGCAA-
TGTTTCAGGATCC-TAMRA 3′ (Eurogentec). p+/−SV40: forward primer
5′ TCCTTCGATAGGGACAAGACAATT 3′, reverse primer 5′GGCAGAGCGA-
CACCTTTAGG 3′ and probe 5′ 6-FAM-CACTGATCATGAACTCCTCTGGATC-
TACTGGCT-TAMRA 3′ (Eurogentec). Replication was determined by the
quantity of signal detected compared to a standard curve of the plasmid.
Western blotting and immunoprecipitation
Cell lysates were harvested in lysis buffer (0.5% NP40, 150 mM
NaCl, 50 mMTris pH 8.0) and protein levels were standardised using a
Bradford Assay.
Forwestern blotting equal amounts of proteinwere boiled in 2 μl of
10× Sample Reducing Agent (Invitrogen) and 5 μl 4× LDS Buffer
(Invitrogen). The lysates were loaded onto a 4–12% gradient gel
(Invitrogen), ran at 200 V for 1 h and transferred onto nitrocellulose
membranes using an iBlot system (Invitrogen). After blocking in 5%
milk PBS-T at room temperature for an hour the membranes were
incubated with primary antibodies and their relevant secondary
antibody according to manufacturer's instructions. The antibodies
used were pAb101 (a monoclonal antibody against Large T Antigen),
HA.11 (Covance) anti-HA epitope to detect HPV16 E1 and HPV11 E1,
phospho-Chk1 (Ser 317) antibody (Cell Signalling Technology#9931),
GTU-88 to detect gamma-tubulin (Abcam), anti-rabbit IgG peroxidise
(Sigma) and anti-mouse IgG peroxidise (GE Healthcare) for develop-
ment. For immunoprecipitation the lysates were incubated on a
spinning rotor overnight at 4 °C with phospho-(Ser/Thr) ATM/ATRsubstrate antibody (Cell Signalling Technology #2851) according to
the manufacturer's instructions. The following morning protein G
sepharose beads (Sigma) were added to the lysate and incubated for
1 h at 4 °C on the rotor. The samples were spun and washed several
times in lysis buffer then boiled in 5 μl 10× Sample ReducingAgent and
15 μl 4× LDS Buffer. Samples were prepared as described above.
MG132 treatment
Cells were treated with 50 μM etoposide, 30 μM MG132 (Calbio-
chem) or a combination of both for 24 h. Cells were harvested for
western blot as described.
In vitro DNA replication assays
Viral in vitro DNA replication assays were performed as previously
detailed (Melendy et al., 1995; Narahari et al, 2006). Thirty
nanograms of template DNA containing the SV40 or HPV origins of
replication (pSV011 or p7974-99) was incubated with 200 ng of SV40
TAg or 40 ng of HPV11 E1 and 20 ng of HPV11 E2, replication buffer
(30 mM HEPES(pH 7.5), 40 mM creatine phosphate, 7 mM MgCl2
0.5 mM DTT, 4 mM ATP, 200 μM CTP, 200 μM UTP, 200 μM GTP,
100 μM dCTP, 100 μM dGTP, 100 μM dTTP, 25 μM dATP), 0.1 mg/ml
acetylated BSA, 0.625 μg creatine phosphokinase (Sigma), 1 μCi αP32
dATP, and 30–50 ng of HEK 293 cell cyto/nucleosolic extract in 10 μl
reactions. Reactions were carried out for one hour at 37 °C and were
terminated by addition of stop buffer (20 mM Tris (pH 7.5), 10 mM
EDTA (pH 8.0), 0.1%SDS, 1 μg/μl proteinase K) for twenty minutes at
37 °C. Replication was evaluated by resolution of replication products
on 0.8% agarose gels followed by phosphorimager autoradiography.
To determine the effect of the kinase inhibitors wortmannin, NU7026,
and KU55933, either dimethylsulfoxide (DMSO) or the inhibitor
dissolved in DMSO, was ﬁrst incubatedwith cellular extracts for 5 min
on ice prior to assembly of the replication reaction. Non-template
plasmid added to the reactions (pUC19) was isolated using standard
protocols, and then either added directly or ﬁrst digested with the
restriction enzyme RsaI to completion, and then phenol:chloroform
extracted and precipitated prior to addition. Several restrictions
enzymes, with varying termini (3′ overhand, 5′ overhang, and blunt
ended) were also used and all types of ends produced very similar
results (data not shown). Quantiﬁcation of DNA replication activity
was by phosphorimager analysis; incorporation of isotope from the
top of the Replication Intermediates all the way through Form I was
quantiﬁed, background from an unused lane was subtracted, and the
results were compared to the DMSO only positive control lane (set to
100%).
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